Literature DB >> 17068199

Protein kinase A exhibits selective modulation of estradiol-dependent transcription in breast cancer cells that is associated with decreased ligand binding, altered estrogen receptor alpha promoter interaction, and changes in receptor phosphorylation.

Mariam H Al-Dhaheri1, Brian G Rowan.   

Abstract

Inhibition of protein kinase A (PKA) promotes estrogen-dependent growth of MCF7 breast cancer cells, although the mechanisms by which PKA regulates estrogen receptor (ER) function remain unclear. In this study elevation of cAMP by forskolin/3-isobutyl-1-methylxanthine (F/I) suppressed estradiol-dependent MCF7 and T47D breast cancer cell growth but not tamoxifen-resistant MCF7-LCC2 cells. Although F/I induced ligand independent activation of ERalpha, F/I also decreased estradiol-dependent reporter gene transcription. Overexpression of PKA or PKA inhibitor (PKI) demonstrated that F/I effects on repression of estradiol action occurred through the PKA pathway. 8CPT-2Me-cAMP, a selective inducer of non-PKA signaling, did not alter ER-dependent transcription. In contrast to F/I effects on reporter genes, F/I exhibited gene-specific effects on endogenous, ER-regulated genes. F/I enhanced estradiol induction of pS2 and cMyc but repressed estradiol induction of cyclin D1 mRNA and protein in MCF7 cells. To explore likely mechanisms by which F/I regulated ER, experiments examined estradiol binding, Hsp90 interaction, promoter recruitment, and ERalpha phosphorylation. F/I decreased estradiol binding and increased Hsp90 association with ERalpha. Chromatin immunoprecipitation revealed that F/I recruited ERalpha to both pS2 and cMyc promoters at earlier times than estradiol, and F/I shifted estradiol recruitment of ERalpha to earlier time points. F/I induced a unique ERalpha phosphorylation profile (increase in serine 305 and decrease in serine 118 phosphorylation) that was distinct from estradiol and estradiol + F/I. Taken together, F/I signaling through PKA selectively regulates estradiol-dependent genes in breast cancer, which is associated with reduced ligand binding and changes in promoter interaction and ERalpha phosphorylation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17068199     DOI: 10.1210/me.2006-0059

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  20 in total

1.  Ligand binding promotes CDK-dependent phosphorylation of ER-alpha on hinge serine 294 but inhibits ligand-independent phosphorylation of serine 305.

Authors:  Jason M Held; David J Britton; Gary K Scott; Elbert L Lee; Birgit Schilling; Michael A Baldwin; Bradford W Gibson; Christopher C Benz
Journal:  Mol Cancer Res       Date:  2012-06-05       Impact factor: 5.852

2.  Stable inhibition of specific estrogen receptor α (ERα) phosphorylation confers increased growth, migration/invasion, and disruption of estradiol signaling in MCF-7 breast cancer cells.

Authors:  B P Huderson; T T Duplessis; C C Williams; H C Seger; C G Marsden; K J Pouey; S M Hill; B G Rowan
Journal:  Endocrinology       Date:  2012-06-25       Impact factor: 4.736

Review 3.  Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy.

Authors:  Wen Zhou; Joyce M Slingerland
Journal:  Nat Rev Cancer       Date:  2014-01       Impact factor: 60.716

4.  Distinctive functions of p160 steroid receptor coactivators in proliferation of an estrogen-independent, tamoxifen-resistant breast cancer cell line.

Authors:  Sudipan Karmakar; Estrella A Foster; Julia K Blackmore; Carolyn L Smith
Journal:  Endocr Relat Cancer       Date:  2010-12-21       Impact factor: 5.678

Review 5.  Estrogens, Neuroinflammation, and Neurodegeneration.

Authors:  Alessandro Villa; Elisabetta Vegeto; Angelo Poletti; Adriana Maggi
Journal:  Endocr Rev       Date:  2016-05-19       Impact factor: 19.871

6.  CARM1 mediates the ligand-independent and tamoxifen-resistant activation of the estrogen receptor alpha by cAMP.

Authors:  Sophie Carascossa; Peter Dudek; Bruno Cenni; Pierre-André Briand; Didier Picard
Journal:  Genes Dev       Date:  2010-04-01       Impact factor: 11.361

Review 7.  Liganded and unliganded activation of estrogen receptor and hormone replacement therapies.

Authors:  Adriana Maggi
Journal:  Biochim Biophys Acta       Date:  2011-05-14

Review 8.  Cellular targets of estrogen signaling in regeneration of inner ear sensory epithelia.

Authors:  Jennifer S McCullar; Elizabeth C Oesterle
Journal:  Hear Res       Date:  2009-02-06       Impact factor: 3.208

9.  A hypersensitive estrogen receptor alpha mutation that alters dynamic protein interactions.

Authors:  Matthew H Herynk; Torsten Hopp; Yukun Cui; Airu Niu; Arnoldo Corona-Rodriguez; Suzanne A W Fuqua
Journal:  Breast Cancer Res Treat       Date:  2009-10-20       Impact factor: 4.872

Review 10.  Estrogenic control of mitochondrial function and biogenesis.

Authors:  Carolyn M Klinge
Journal:  J Cell Biochem       Date:  2008-12-15       Impact factor: 4.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.